HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
Over 80% of HIV-1 infected persons are also seropositive for HSV-2. Increasingly, clinical
and epidemiologic evidence show the role of HSV in increasing HIV infectiousness. The
evidence suggests that that HSV is an important cofactor in HIV transmission.
The trial's purpose is to assess the reduction in HIV shedding associated with valacyclovir
for suppression of HSV-2 reactivation.
This proof-of-concept, randomized, double-blind, placebo controlled crossover trial of 20
HIV/HSV-2 co-infected men, assessed the effects of daily valacyclovir on HIV-1 levels in the
plasma and rectal mucosa secretions.
Phase:
Phase 3
Details
Lead Sponsor:
University of Washington
Collaborators:
Asociación Civil Impacta Salud y Educación, Peru GlaxoSmithKline